|
Stem and progenitor cell alterations in myelodysplastic syndromes
|
Feb 2017
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life
|
Jan 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.
|
Aug 2013
|
Blood
|
aplastic anemia
|
|
The myelodysplastic syndrome as a prototypical epigenetic disease.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Genetics of Progression From MDS to Secondary Leukemia
|
Jul 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria
|
Sep 2014
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia
|
May 2017
|
Blood
|
acute myeloid leukemia (AML)
|
|
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
|
Apr 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
|
Aug 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria
|
Feb 2014
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
